Short, Long Sleep Duration Tied to Microvascular Disease in Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 7, 2024 -- For individuals newly diagnosed with type 2 diabetes mellitus (T2DM), both short and long sleep duration are associated with microvascular disease, according to a study scheduled to be presented at the annual meeting of the European Association for the Study of Diabetes, being held from Sept. 9 to 13 in Madrid.
Mette S. Johansen, from Odense University Hospital in Denmark, and colleagues explored the relationship between sleep duration and the presence of microvascular disease among individuals newly diagnosed with T2DM in a cross-sectional analysis. Sleep duration at night was measured using accelerometers worn for a period of 10 days and was categorized into short (less than seven hours), optimal (seven to less than nine hours), and long (at least nine hours).
Overall, 396 participants had valid sleep duration measures, as well as urine albumin/creatinine ratio measurement and eye examination (used to define microvascular disease). The researchers found that 12, 60, and 28 percent of the participants had short, optimal, and long sleep duration, respectively. Within these categories, the prevalence of microvascular damage was 38, 18, and 31 percent, respectively. Both short and long sleep duration were significantly associated with microvascular disease (odds ratios, 2.63 and 2.29, respectively). Age accentuated the association between short sleep duration and microvascular disease for participants aged younger than 62 years compared with those aged older than 62 years.
"Age amplifies the association between short sleep duration and microvascular disease, suggesting increased vulnerability among older individuals," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
New Mothers Face Significant Loss of Uninterrupted Sleep
THURSDAY, June 12, 2025 -- New mothers face a significant loss of uninterrupted sleep through week 13 postpartum, according to a study presented at SLEEP 2025, the...
Daytime Napping Behaviors in Middle-Aged, Older Adults Impact Mortality Risk
WEDNESDAY, June 11, 2025 -- Certain objectively measured daytime napping behaviors are associated with an increased risk for mortality for middle- to older-aged adults, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.